Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions. Overall, Alexion has posted an average positive earnings surprise of 1.68% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion missed on earnings expectations in the fourth quarter of 2016. Our consensus called for EPS of $1.10, and the company reported EPS of $1.07 (these figures include stock-based compensation expense).
Revenue: Revenues were also below expectations. Alexion posted revenues of $831 million, compared to our consensus estimate of $837 million.
Key Stats: Solirus sales declined 8.7% in the quarter to $749 million.
2017 Guidance: The company expects adjusted earnings per share to be in the range of $5.00 to $5.25. It projects revenues to be in the range of $3.4 to $3.5 billion. The Zacks Consensus Estimate for earnings was $4.80 per share while for sales it was $3.53 billion.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Image: Bigstock
Alexion (ALXN) Misses on Q4 Earnings and Revenues
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions. Overall, Alexion has posted an average positive earnings surprise of 1.68% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion missed on earnings expectations in the fourth quarter of 2016. Our consensus called for EPS of $1.10, and the company reported EPS of $1.07 (these figures include stock-based compensation expense).
Revenue: Revenues were also below expectations. Alexion posted revenues of $831 million, compared to our consensus estimate of $837 million.
Key Stats: Solirus sales declined 8.7% in the quarter to $749 million.
2017 Guidance: The company expects adjusted earnings per share to be in the range of $5.00 to $5.25. It projects revenues to be in the range of $3.4 to $3.5 billion. The Zacks Consensus Estimate for earnings was $4.80 per share while for sales it was $3.53 billion.
Alexion Pharmaceuticals, Inc. Price and EPS Surprise
Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>